SPARC Reports Narrower Net Loss in Q1 Despite Revenue Decline Aug 04, 2025
Sun Pharma Advanced Research Co (SPARC) reported Q1 financial results with a reduced net loss of ₹518.70 crore, down from ₹959.00 crore in the previous year, despite a 42.70% revenue decline to ₹96.40 crore. Total expenses decreased to ₹705.90 crore from ₹1,138.70 crore. The company recorded other income of ₹91.40 crore. Key expenses included employee benefits (₹313.20 crore), clinical trials (₹55.40 crore), professional charges (₹100.70 crore), and finance costs (₹61.90 crore). SPARC operates in the Pharmaceutical Research and Development segment and maintains its 'Going Concern' status with support from its promoter group entity.
SPARC Shares Plummet 19% as Psoriasis Drug Fails Phase 2 Trials Jun 04, 2025
Sun Pharma Advanced Research Company: Psoriasis Drug Fails Phase 2 Trials, Shares Plummet Jun 04, 2025
Sun Pharma Advanced Research to Discuss Fund Raising Proposal in Upcoming Board Meeting May 12, 2025
SPARC Advances Cancer Treatment: IND Application for SBO-154 Submitted to FDA Mar 31, 2025